Rare / orphan disease drugs

Discover the landscape of Rare / orphan disease drugs in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Rare / orphan disease drugs, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance
CompanyDeals

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Group and the China Association Against Epilepsy (CAAE) officially signed a strategic collaboration agreement, committing to a five‑year partnership spanning discipline development, talent cultivation and public welfare assistance.…

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Mirxes Partners with Thailand's National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs "Cancer Moonshot 2056"

Mirxes Partners with Thailand’s National Cancer Institute on Blood‑Based Colorectal Cancer Screening – 2,000‑Subject Prospective Triage Study Backs “Cancer Moonshot 2056”

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Zelgen's ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer
CompanyDrug

Zelgen’s ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma
CompanyDrug

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma

CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma
CompanyDrug

CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma

MSD's Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension
CompanyDrug

MSD’s Winrevair Accepted for Priority Review by FDA for Pulmonary Arterial Hypertension

CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment
CompanyDrug

CSPC Pharma Receives NMPA Approval for Hydroxocobalamine in Pediatric MMA Treatment

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT
CompanyDrug

CANbridge’s Geruining Approved for Gaucher Disease Treatment: First Domestically Developed ERT

UCB's Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder
CompanyDrug

UCB’s Fenfluramine Shows Positive Results in Phase III GEMZ Study for CDKL5 Deficiency Disorder

Sanofi's Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment
CompanyDrug

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Show More